ZTS - ZTS ゾエティス （）

Despite cooling inflation , investing in farmland remains an excellent way to hedge against higher prices. That’s because it’s a real asset that does well in periods of inflation and over more extended periods because of ongoing food scarcity issues. According to Barron’s reporting , the 25-year average annual return for farmland through March 2021 was 11.2%, 160 basis points higher than the S&P 500 . As they say about land, “They’re not making it anymore.” And, in the case of farmland, it’s shrinking every year. For example, between 2002 and 2022, approximately 11 million acres were lost to development in the U.S. Add in the amount of food that will need to be produced in the next 30 years to meet the growing global population and it seems unlikely that farmland will lose much of its value. Demand and increasing scarcity are a recipe for higher prices. One of the easiest farmland investment strategies involves buying stocks in agriculture-related businesses such as combine and tractor makers.

Zoetis (NYSE: ZTS ) has outperformed the market over the past 10 years by 7.77% on an annualized basis producing an average annual return of 17.66%. Currently, Zoetis has a market capitalization of $76.13 billion. Buying $1000 In ZTS: If an … Full story available on Benzinga.com

https://www.investing.com/news/stock-market-news/zoetis-analyst-day-modestly-underperformed--goldman-sachs-432SI-3092294

Zoetis Inc. (NYSE:ZTS) is hosting an investor day at 9:00 a.m. ET today at the New York Stock Exchange, where the company will dive into its compelling growth ambitions, its innovative and robust R&D pipeline and its financial roadmap to continue delivering shareholder value, as it Shapes Animal Health for the Next Decade. During today’s presentations, Chief Executive Officer Kristin Peck,

Zoetis (NYSE: ZTS ) shareholders may have a new reference point to be excited about, even after witnessing some favorable developments through the company''s first quarter 2023 announcements. Even after outperforming other peers in the sector, such as Bausch Health Companies (NYSE: BHC ) and Elanco Animal Health (NYSE: ELAN ) by as much as 32% and 75%, respectively, analyst ratings still suggest that Zoetis stock has a double-digit upside potential ceiling from today''s prices. News has broken out regarding JAB''s acquisition of the pet insurance platform Pumpkin. In an attempt to expand its global leadership in the pet insurance industry, JAB''s acquisition indirectly benefitted Zoetis, which still is looking to maintain its minority interest in the platform. A continued commercial partnership and financial interests will no doubt accrue to Zoetis'' financials moving forward. While the transaction terms have not been disclosed, some analysts can derive some valuation given the sixty-five thousand pets insured since Pumpkin''s launch in 2020.

Despite cooling inflation , investing in farmland remains an excellent way to hedge against higher prices. That’s because it’s a real asset that does well in periods of inflation and over more extended periods because of ongoing food scarcity issues. According to Barron’s reporting , the 25-year average annual return for farmland through March 2021 was 11.2%, 160 basis points higher than the S&P 500 . As they say about land, “They’re not making it anymore.” And, in the case of farmland, it’s shrinking every year. For example, between 2002 and 2022, approximately 11 million acres were lost to development in the U.S. Add in the amount of food that will need to be produced in the next 30 years to meet the growing global population and it seems unlikely that farmland will lose much of its value. Demand and increasing scarcity are a recipe for higher prices. One of the easiest farmland investment strategies involves buying stocks in agriculture-related businesses such as combine and tractor makers.

Zoetis (NYSE: ZTS ) has outperformed the market over the past 10 years by 7.77% on an annualized basis producing an average annual return of 17.66%. Currently, Zoetis has a market capitalization of $76.13 billion. Buying $1000 In ZTS: If an … Full story available on Benzinga.com

https://www.investing.com/news/stock-market-news/zoetis-analyst-day-modestly-underperformed--goldman-sachs-432SI-3092294

Zoetis Inc. (NYSE:ZTS) is hosting an investor day at 9:00 a.m. ET today at the New York Stock Exchange, where the company will dive into its compelling growth ambitions, its innovative and robust R&D pipeline and its financial roadmap to continue delivering shareholder value, as it Shapes Animal Health for the Next Decade. During today’s presentations, Chief Executive Officer Kristin Peck,

Zoetis (NYSE: ZTS ) shareholders may have a new reference point to be excited about, even after witnessing some favorable developments through the company''s first quarter 2023 announcements. Even after outperforming other peers in the sector, such as Bausch Health Companies (NYSE: BHC ) and Elanco Animal Health (NYSE: ELAN ) by as much as 32% and 75%, respectively, analyst ratings still suggest that Zoetis stock has a double-digit upside potential ceiling from today''s prices. News has broken out regarding JAB''s acquisition of the pet insurance platform Pumpkin. In an attempt to expand its global leadership in the pet insurance industry, JAB''s acquisition indirectly benefitted Zoetis, which still is looking to maintain its minority interest in the platform. A continued commercial partnership and financial interests will no doubt accrue to Zoetis'' financials moving forward. While the transaction terms have not been disclosed, some analysts can derive some valuation given the sixty-five thousand pets insured since Pumpkin''s launch in 2020.

Related Stocks: IVV , AGG , NVDA , THC , ZTS ,

Zoetis Inc. (ZTS)’s stock has witnessed a price declined of -1.71% from the previous close with its current price standing at $168.07. Its current price is -18.14% under its 52-week high of $205.30 and 35.38% more than its 52-week low of $124.15. Based on the past 30-day period, the stock price is -2.15% below the […]

Zoetis Inc. - Consensus Indicates Potential 25.1% Upside

Zoetis Inc. (NYSE:ZTS) traded at $165.89 at close of the session on Tuesday, 01/24/23, made a downward move of -0.52% on its previous day’s price. Looking at the stock we see that its previous close was $166.75 and the beta (5Y monthly) reads 0.72 with the day’s price range being $145.20 – $186.73. The company … Zoetis Inc. (NYSE: ZTS) Is Down -0.52% – Is It Capable Of A Rally? Read More »

Another growth lever to watch in manufacturing is that of the Mangalore API facility. Here the USFDA approval is expected in H2FY24.